Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04848142
Other study ID # PSYGEN
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 7, 2021
Est. completion date October 13, 2023

Study information

Verified date October 2023
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The participants are being asked to take part in this research study because the participant is a child who has been diagnosed with cancer and has completed genetic testing to find out if the participant has a variant in a gene that may predispose the participant to cancer, and/or the participants are the parents (i.e., guardian/caregiver) of this child. This research is being done to understand how finding out the results of genetic testing during childhood impacts the participant and family. The investigator will compare the emotions and behavior of parents and children based on the genetic testing results. Primary Objective - Examine the impact of genetic testing result disclosure for a pathogenic (P)/likely pathogenic (LP) germline variant in a known cancer predisposing gene versus negative results on parent adjustment (i.e., emotional functioning, cancer worry, symptom interpretation, and genetic testing related worry/distress). - Examine the impact of genetic testing result disclosure for a P/LP germline variant versus negative results on parenting (i.e., responses to children's symptoms, overprotectiveness, parent-child communication, cohesion, and expressivity in the family). Exploratory Objectives - Examine the impact of genetic testing result disclosure (P/LP versus negative results) on child adjustment (i.e. emotional functioning, cancer worry, self-perception, and life meaning and purpose). - Examine the impact of disclosing a variant of uncertain significance (VUS) on parent adjustment, parenting, and child adjustment. - Examine the indirect association between genetic testing result disclosure (P/LP versus negative results) and child adjustment through parental adjustment and parenting behavior. - Qualitatively identify children and parents' perspectives of how disclosure of a cancer predisposition has affected children's emotional, social, personal, and familial functioning.


Description:

A mixed methods approach, including questionnaires and qualitative interviews with children and their parents. Participants ("Primary Strata:" parents (i.e., guardians/caregivers) and children age ≥ 8 years, n=132; "Parent Only Strata:" parents of children age < 8 years, n=66) will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years, n=30) with P/LP variants (and who are aware of their result status) and their parents (n=30) to obtain more open-ended information about the impact of genetic testing result disclosure, family communication about testing results, and their perception of result implications.


Recruitment information / eligibility

Status Completed
Enrollment 199
Est. completion date October 13, 2023
Est. primary completion date October 13, 2023
Accepts healthy volunteers No
Gender All
Age group 8 Years and older
Eligibility Inclusion Criteria: Primary Strata - Patient underwent germline genetic testing as offered through the SJCRH Cancer Predisposition Program with results disclosed to patient and/or parents (i.e., of testing results are not a criterion for eligibility) - Patient's age at the time of initial germline result disclosure was birth - 17 years of age (inclusive) - Patient had diagnosis of malignancy (or benign tumor; e.g., craniopharyngioma) prior to germline testing - A parent/legal guardian/caregiver is willing to participate in the research study and provide consent - Participant family is fluent in English for completion of questionnaires (able to speak and read) - Patient is currently 8 years of age or older Parent Only Strata - Parent (i.e., guardian/caregiver) of a patient who underwent germline genetic testing as offered through the SJCRH Cancer Predisposition Program with results disclosed to patient and/or parents 1 - 3 years (inclusive) previously (Note- patient's knowledge of testing results are not a criterion for eligibility) - Parent of a patient whose age at the time of initial germline result disclosure was birth - 17 years of age (inclusive) - Parent of a patient with a diagnosis of malignancy (or benign tumor; e.g., craniopharyngioma) prior to germline testing - Parent/caregiver is a legal guardian willing to participate in the research study and provide consent - Participant family is fluent in English for completion of questionnaires (able to speak and read). - Parent of a patient currently younger than 8 years of age. Exclusion Criteria: - Inability or unwillingness of research participant or parent (i.e., guardian/caregiver) to give informed consent - Parent is under the age of 18 years - Parent has evidence of significant cognitive deficits (per medical report) that would interfere with the ability to comprehend questionnaires - Research participant's medical status or condition precludes completion of the study (as determined by the medical team, patient, or parent)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States St.Jude Children's Research Hospital Memphis Tennessee

Sponsors (1)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fear of Cancer Recurrence Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Fear of Cancer Recurrence - Short Form. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Cancer Information Questionnaire for Parents Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the Cancer Information Questionnaire for Parents. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Multidimensional Impact of Cancer Risk Assessment Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Multidimensional Impact of Cancer Risk Assessment. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Brief Symptom Inventory 18 Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Brief Symptom Inventory 18. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Impact of Event Scale Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Impact of Event Scale - Revised. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Psychological Adaptation to Genetic Information Scale Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Psychological Adaptation to Genetic Information Scale-Modified. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Symptom Interpretation Questionnaire-Parent Report Independent two-sample t-tests will assess statistical parental adjustment differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the Symptom Interpretation Questionnaire-Parent Report. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Parent-Adolescent Communication Scale Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) of parent- and child-reports on the Parent-Adolescent Communication Scale. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Family Environment Scale Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Family Environment Scale-Revised. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Parental Bonding Instrument Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the child-reported Parental Bonding Instrument. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Parent Protection Scale Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Parent Protection Scale. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Openness to Discuss Cancer in the Family Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Openness to Discuss Cancer in the Family. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Child Vulnerability Scale Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Child Vulnerability Scale. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
Primary Adult Responses to Children's Symptoms Independent two-sample t-tests will assess statistical parenting differences between group means (i.e., parents of children with pathologic/likely pathologic vs. negative genetic testing result) on the parent-reported Adult Responses to Children's Symptoms. Only in the situation of outliers, two-sample Mann-Whitney U tests will be used for testing purposes. Day 0
See also
  Status Clinical Trial Phase
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Withdrawn NCT04719416 - Relaxation Therapy in Pediatric Oncology N/A
Completed NCT01645436 - Physical Activity in Pediatric Cancer (PAPEC) N/A
Completed NCT04409301 - Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05425043 - Granulocyte Transfusions After Umbilical Cord Blood Transplant N/A
Recruiting NCT05071859 - Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting NCT03241251 - Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Recruiting NCT05569512 - Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Phase 1/Phase 2
Enrolling by invitation NCT05294380 - Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
Completed NCT02665819 - Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility. N/A
Completed NCT02675166 - Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
Not yet recruiting NCT05454163 - Post-radiotherapy Rhinosinusitis in Children
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Withdrawn NCT01828502 - Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer Phase 2
Completed NCT02032121 - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors N/A
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1